The stock of Neos Therapeutics Inc (NASDAQ:NEOS) hit a new 52-week low and has $5.25 target or 14.00% below today’s $6.11 share price. The 6 months bearish chart indicates high risk for the $97.88 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $5.25 price target is reached, the company will be worth $13.70 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 61,550 shares traded hands. Neos Therapeutics Inc (NASDAQ:NEOS) has declined 37.91% since March 28, 2016 and is downtrending. It has underperformed by 42.63% the S&P500.
Analysts await Neos Therapeutics Inc (NASDAQ:NEOS) to report earnings on November, 8. They expect $-1.61 earnings per share, down 159.68% or $0.99 from last year’s $-0.62 per share. After $-1.58 actual earnings per share reported by Neos Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.90% negative EPS growth.
Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage
Out of 4 analysts covering Neos Therapeutics (NASDAQ:NEOS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neos Therapeutics has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) earned “Outperform” rating by Wells Fargo on Friday, February 19. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The company was maintained on Thursday, November 12 by RBC Capital Markets. The rating was initiated by BMO Capital Markets on Monday, August 17 with “Outperform”. The rating was initiated by BMO Capital Markets with “Outperform” on Wednesday, June 29. As per Monday, August 17, the company rating was initiated by RBC Capital Markets. JMP Securities initiated Neos Therapeutics Inc (NASDAQ:NEOS) on Monday, August 17 with “Market Outperform” rating.
According to Zacks Investment Research, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.”
More notable recent Neos Therapeutics Inc (NASDAQ:NEOS) news were published by: Quotes.Wsj.com which released: “News Neos Therapeutics Inc.NEOS” on April 22, 2015, also Globenewswire.com with their article: “Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla …” published on November 10, 2015, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 19, 2016. More interesting news about Neos Therapeutics Inc (NASDAQ:NEOS) were released by: Globenewswire.com and their article: “Neos Therapeutics Announces Pricing of Initial Public Offering” published on July 23, 2015 as well as Businesswire.com‘s news article titled: “Neos Therapeutics Announces Trade Name Cotempla XR-ODTâ„¢ for its …” with publication date: May 20, 2015.
NEOS Company Profile
Neos Therapeutics, Inc., incorporated on June 15, 2009, is a pharmaceutical company. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. The Firm has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). The Company’s product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The Company’s branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. The Company’s modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.